Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07007117 · ClinicalTrials.gov registry record · Phase 1
PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma
A Phase 1 study of High-risk Neuroblastoma and Refractory Neuroblastoma, sponsored by Stephan Grupp MD PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT07007117 is a Phase 1 study of High-risk Neuroblastoma and Refractory Neuroblastoma that is actively recruiting participants, run by Stephan Grupp MD PhD. The registered enrollment target is 38 participants, below the 61-participant average among 9 other High-risk Neuroblastoma trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07007117, a Phase 1 study of High-risk Neuroblastoma and Refractory Neuroblastoma, is actively recruiting participants, sponsored by Stephan Grupp MD PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a first in human dose escalation trial to determine the safety of administering PHOX2B PC-CAR T cells in patients with advanced, high-risk neuroblastoma.
Conditions Studied
Interventions
- BIOLOGICAL PHOX2B PC-CAR T Cells
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2025-06-20 |
| Est. Completion | 2035-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07007117
The ClinicalTrials.gov registry entry for NCT07007117 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 9 other High-risk Neuroblastoma trials with a reported enrollment target (38% lower). The listed sponsor is Stephan Grupp MD PhD, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with High-risk Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which PHOX2B PC-CAR T Cells is the first listed.
NCT07007117 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07007117 about?
NCT07007117 is a clinical study titled "PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma". This is a first in human dose escalation trial to determine the safety of administering PHOX2B PC-CAR T cells in patients with advanced, high-risk neuroblastoma.
What is the current status of trial NCT07007117?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2025-06-20. Estimated completion is 2035-06-30.
What conditions does trial NCT07007117 study?
This clinical trial studies the following conditions: High-risk Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma.
What interventions are being tested in trial NCT07007117?
The interventions under investigation include: PHOX2B PC-CAR T Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT07007117?
This trial is sponsored by Stephan Grupp MD PhD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07007117 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High-risk Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
RECRUITING · Phase 1
-
Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
RECRUITING · Phase 1
-
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
RECRUITING · Phase 1
-
Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors
RECRUITING
-
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
RECRUITING · Phase 2
-
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.